Anti-Hypertensive Drugs - Switzerland

Switzerland

Highlights

The Anti-Hypertensive Drugs market in Switzerland is expected to witness significant growth in the coming years.
According to projections, the revenue in this market is anticipated to reach US$137.30m in 2024.
Furthermore, it is expected to maintain a steady annual growth rate (CAGR 2024-2029) of -0.17%, ultimately leading to a market volume of US$136.20m by 2029.
When considering global comparisons, it is worth noting that United States is projected to generate the highest revenue in the Anti-Hypertensive Drugs market, with an estimated value of US$12.29bn in 2024.
The significance of this market can be further exemplified by comparing the revenue figures from different countries.
In Switzerland, the market for anti-hypertensive drugs is characterized by a high demand for innovative and personalized treatment options.

Key regions:

Market definitionIn-Scope/Out-of-scopeMarket structureReportsMethodology

Switzerland, known for its chocolate, cheese, and watches, is also a country with a high prevalence of hypertension. Hypertension affects approximately one in three adults in Switzerland, leading to a high demand for anti-hypertensive drugs.

Customer preferences: In Switzerland, patients prefer to take medication that is effective and has minimal side effects. They also prefer to take medication that is easy to administer and has a low pill burden. Patients in Switzerland are generally well-informed about their health and are willing to pay a premium for drugs that meet their preferences.

Trends in the market: The anti-hypertensive drugs market in Switzerland is growing steadily due to the high prevalence of hypertension in the country. The market is dominated by branded drugs, but the availability of generic drugs is increasing. This has led to price competition among drug manufacturers, resulting in lower prices for patients.

Local special circumstances: Switzerland has a unique healthcare system where patients have a high level of autonomy in choosing their healthcare provider and treatment. The Swiss government regulates the price of drugs, which has led to lower drug prices compared to other countries in Europe. Additionally, Switzerland has a high level of pharmaceutical innovation, with many drug manufacturers based in the country.

Underlying macroeconomic factors: Switzerland has a strong economy and a high standard of living, which has led to a high demand for healthcare services. The aging population in Switzerland is also driving the demand for anti-hypertensive drugs, as hypertension is more prevalent in older adults. The Swiss healthcare system is well-funded and has a high level of access to healthcare services, which has led to a high level of demand for anti-hypertensive drugs.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.